Biotech

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 25.01.2023.

#PharmaScrip
#biotech
#lifesciences
#agreement
#license
#biopharma
#biotechpodcast
#Massachusetts
#monoclonal
#antibodies

@Labiotech_eu shared
On Jan 23, 2023
Beyond Biotech - the podcast from Labiotech has over 10,000 podcast downloads 🎉! Haven't listened to our biotech podcast yet? You can find the show on your favorite app from the following page 👉 https://t.co/QVW3KX9G7s #biotech #biotechpodcast #lifesciencepodcast https://t.co/VANPm8s2A2
Open
Beyond Biotech - the podcast from Labiotech

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around ...

@PharmaScrip shared
On Jan 24, 2023
Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model https://t.co/4amC8hDjKj #PharmaScrip
Open
Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model

Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model

<p><strong><span style="color: #111111;">Emerging Company Profile: </span></strong><span style="color: #111111;">The UK biotech is working to expedite its portfolio of acquired drug ...

@biospace shared
On Jan 20, 2023
#Massachusetts-based @DiscMedicine inked an exclusive #license #agreement with Mabwell Therapeutics to gain access to its portfolio of #monoclonal #antibodies against the transmembrane serine protease 6 protein. https://t.co/bHtf9OdUEy #lifesciences #biopharma #biospace
Open
Weeks After Reverse Merger, Disc Expands Hematologic Pipeline

Weeks After Reverse Merger, Disc Expands Hematologic Pipeline

Disc Medicine announced it had inked an exclusive license agreement with Mabwell Therapeutics for the latter’s portfolio of monoclonal antibodies against the TMPRSS6 protein.

@matthewherper shared
On Jan 21, 2023
RT @adamfeuerstein: This week's podcast: We talked to @nathanvardi about his new biotech book, "For Blood and Money." We asked him: How much greed, resentment, lust for power and ego is required to develop blockbuster cancer drugs? In the amazing story he tells: A lot! https://t.co/knxUqIfUZZ
Open
Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

Where do new drugs come from? Does science need billionaires? And do normal people care about messenger RNA? Find out on the latest episode of "The Readout LOUD" #podcast.

@Labiotech_eu shared
On Jan 20, 2023
Single-cell microfluidic-based techniques continue to be a key enabling technology for cell engineering, according to Sphere Fluidics. 👇🏻 #biotech #lifesciences #news https://t.co/w1iRIgxtpy
Open
The future of single-cell microfluidics in cell engineering

The future of single-cell microfluidics in cell engineering

Single-cell microfluidic-based techniques continue to be a key enabling technology for cell engineering, according to Sphere Fluidics.

@PharmaScrip shared
On Jan 25, 2023
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023 https://t.co/a58eNRvP2D #PharmaScrip
Open
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

<p>India had a busy deals calendar in 2022, with companies led by Biocon striking large M&amp;A deals while PE activity declined. <em>Scrip</em> pieced together data for infographics on ...

@PharmaScrip shared
On Jan 24, 2023
How HALO Slip Proved Costly For CinCor In AstraZeneca Talks https://t.co/Q8QHDgEW5F #PharmaScrip
Open
How HALO Slip Proved Costly For CinCor In AstraZeneca Talks

How HALO Slip Proved Costly For CinCor In AstraZeneca Talks

<p>Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a ...

@GENbio shared
On Jan 20, 2023
RT @KevinADavies: Excited to host @matthewcobb at @HarvardBooks next Tuesday (6 pm ET), discussing his new book "As Gods" @BasicBooks (and maybe his next one!) https://t.co/R4qngwF8dV https://t.co/2dyEqDAic3
Open
Virtual Event: Matthew Cobb

Virtual Event: Matthew Cobb

As Gods: A Moral History of the Genetic Age in conversation with KEVIN DAVIES Harvard Book Store, the Harvard University Division of Science, and the Harvard Library welcome …